

Add data to your insights.



Quantitative Data for Your Ocular Surface Assessment

- 💧 A healthy ocular surface is essential for good vision.
- 💧 Since 70% of the total refractive power occurs at the tear film surface¹, it is essential to evaluate the tear film when managing ocular surface disease.
- 💧 Tear osmolarity is an important biomarker of ocular surface health.

“The core mechanisms of dry eye are driven by tear hyperosmolarity & tear film instability.”

- DEWS, 2007


Diagnose:

Test both eyes to uncover abnormal osmolarity and determine severity.




Abnormal osmolarity is defined by:

• An elevated reading, >300 mOsm/L, indicating loss of homeostasis.³


• **OR**, When the inter-eye difference is >8 mOsm/L, indicating instability of the tear film.³



Epithelial Cell Health




• Left undiagnosed and untreated, epithelial cell death and visual fluctuations can occur.⁴⁻⁵




If a patient is symptomatic with normal osmolarity, additional considerations include:

- Conjunctival chalasis
- Mild allergic conjunctivitis
- Epithelial Basement Membrane Dystrophy (EBMD)
- Other



Variability is a hallmark of the disease.⁶



THE GREATER
the osmolarity,
THE GREATER
the variability.

The point-of-care TearLab Diagnostic Test provides precise and predictive information.

PRECISE:

Clinical Test	CV
Osmolarity	< 1.5%
Glucose	≥ 5.0%
Cholesterol	> 4.0%

More precise than other universally accepted point-of-care tests such as cholesterol and glucose.⁷⁻⁹

PREDICTIVE:




89

% Predictive
of dry eye¹⁰

Manage:

Use TearLab osmolarity data to inform your treatment plan based on disease severity and manage patient progress by evaluating therapeutic effectiveness.¹¹⁻¹³

Response to Therapy: Abnormal osmolarity decreases with effective treatment.



The point-of-care TearLab Diagnostic Test provides **quick, precise and predictive** information regarding tear osmolarity, an important biomarker of ocular surface health.

 **TearLab**

855.832.7522 | TearLab.com

References

1. Dawson D, Watsky M, Geoski D, Edelhauser H. Cornea and Sclera. Duanes Ophthalmology, New York.
2. DEWS Definition and Classification Subcommittee. The definition and classification of dry eye disease: report of the Definition and Classification Subcommittee of the International Dry Eye WorkShop (2007). *Ocul Surf*. 2007;5:75-92.
3. Lemp MA, et al. Tear osmolarity in the diagnosis and management of dry eye disease. *Am J Ophthalmol*. 2011; 151: 792-798.
4. Kam W, et al. *Invest Ophthalmol Vis Sci*. 2016; 57:E-abstract 6181.
5. Nochez Y, et al. Evaluation of tear film quality with a double-pass scattering index. ARVO E-Abstract 3754. 2011.
6. Keech A, Senchyn M, Jones, L. Impact of time between collection and collection method on human tear fluid osmolarity. *Current Eye Research*, Early Online, 1-9, 2013.
7. FDA K083184 Within Run CV@318mOsm/L.
8. Kimberly MM, et al. Variability among five over-the-counter blood glucose monitors. *Clinica Chim Acta*. 2006; 364: 292-297.
9. Volles DF, et al. Analytic and clinical performance of two compact cholesterol-testing devices. *Pharmacotherapy*. 1998; 18:1.
10. Tomlinson A. Tear film osmolarity: determination of a referent for dry eye diagnosis. *Invest Ophthalmol Vis Sci*. 2006 Oct; 47 (10): 4309-15.
11. Sullivan BD, Crews LA, Sonmez B, et al. Clinical utility of objective tests for dry eye disease: variability over time and implications for clinical trials and disease management. *Cornea*. Sept 2012;31 (9): 1000-1008.
12. Comez AT, et al. Effects of lubricating agents with different osmolalities on tear osmolarity and other tear function tests in patients with dry eye. *Curr Eye Res*. Nov 2013; 38 (11): 1095-1103.
13. Donnemfeld ED, Holland EJ, Buccini FA, et al. Effect of oral re-esterified omega-3 nutritional supplementation on dry-eye disease: double-masked randomized placebo-controlled study. Poster session presented at: American Society of Cataract and Refractive Surgery; 2015 April 17-21; San Diego, CA.

© 2016 TearLab Corp. 920291 Rev A



Distributed by:

IQ Medical Pty Ltd

2/86 Mary Street, Unley SA 5061

Phone (08) 8357 8022 | Email sales@iqmedical.com.au

Web www.iqmedical.com.au